Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.53 |
| ▸ | RHOA | P61586 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22356493 | 0.98 | SYK (0.62) | SYKCYP3A4TSHRHDAC6KMT2A | |
| SCHEMBL29819598 | 0.94 | CYP3A4 (0.74) | SYKCYP3A4TSHRHDAC6KMT2A | |
| SCHEMBL12513290 | 0.94 | CYP3A4 (0.74) | SYKCYP3A4TSHRHDAC6KMT2A | |
| SCHEMBL1318687 | 0.91 | SYK (0.63) | SYKCYP3A4TSHRHDAC6KMT2A | |
| SCHEMBL3809017 | 0.91 | SYK (0.55) | SYKCYP3A4TSHRHDAC6KMT2A | |
| SCHEMBL28888084 | 0.90 | SYK (0.58) | SYKCYP3A4TSHRHDAC6KMT2A | |
| SCHEMBL4568691 | 0.89 | NFKB1 (0.63) | SYKCYP3A4TSHRHDAC6KMT2A | |
| SCHEMBL657020 | 0.88 | SYK (0.72) | SYKCYP3A4TSHRHDAC6KMT2A | |
| SCHEMBL23868692 | 0.88 | SYK (0.55) | SYKCYP3A4TSHRHDAC6KMT2A | |
| SCHEMBL11616820 | 0.87 | SYK (0.55) | SYKCYP3A4TSHRHDAC6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189892-A1 | MELAMINE DERIVATIVES AS POTENT ANTI-CANCER AGENTS | Parker Hughes Institute (US) | 2002-03-27 | — | — | EP | claimed |
| US-6262053-B1 | EFFECTIVE FOR TREATING TUMOR CELLS AND PARTICULARLY EFFECTIVE TO INDUCE APOPTOSIS IN LEUKEMIA AND BREAST TUMOR CELLS. | PARKER HUGHES INSTITUTE | 2001-07-17 | — | — | US | claimed |
| WO-2000078738-A1 | MELAMINE DERIVATIVES AS POTENT ANTI-CANCER AGENTS | PARKER HUGHES INSTITUTE (US) | 2000-12-28 | — | — | WO | claimed |
| CN-111065628-B | Novel triazine derivative and photosensitive composition comprising the same | 株式会社特雷尔 | 2023-06-02 | — | — | CN | disclosed |
| US-20230020941-A1 | COMPOSITION, THERMALLY CONDUCTIVE MATERIAL, THERMALLY CONDUCTIVE SHEET, AND DEVICE WITH THERMALLY CONDUCTIVE LAYER | FUJIFILM CORPORATION (JP) | 2023-01-19 | — | — | US | disclosed |
| US-11427551-B2 | Triazine derivative and photosensitive composition comprising same | TREEEL CO., LTD (KR) | 2022-08-30 | — | — | US | disclosed |
| US-20220216126-A1 | MANUFACTURING METHOD FOR THERMAL CONDUCTIVE LAYER, MANUFACTURING METHOD FOR LAMINATE, AND MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE | FUJIFILM CORPORATION (JP) | 2022-07-07 | — | — | US | disclosed |
| US-20220135861-A1 | COMPOSITION FOR FORMING THERMALLY CONDUCTIVE MATERIAL, THERMALLY CONDUCTIVE MATERIAL, AND SURFACE-MODIFIED INORGANIC SUBSTANCE | FUJIFILM CORPORATION (JP) | 2022-05-05 | — | — | US | disclosed |
| US-20210301180-A1 | COMPOSITION, THERMALLY CONDUCTIVE SHEET, AND DEVICE WITH THERMALLY CONDUCTIVE LAYER | FUJIFILM CORPORATION (JP) | 2021-09-30 | — | — | US | disclosed |
| US-20200262798-A1 | NOVEL TRIAZINE DERIVATIVE AND PHOTOSENSITIVE COMPOSITION COMPRISING SAME | TREEEL CO., LTD (KR) | 2020-08-20 | — | — | US | disclosed |
| US-20200262798-A1 | NOVEL TRIAZINE DERIVATIVE AND PHOTOSENSITIVE COMPOSITION COMPRISING SAME | TREEEL CO., LTD (KR) | 2020-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427551-B2 | Triazine derivative and photosensitive composition comprising same | TYR, CRY2, CRY1 | SYK 1366/4885CYP3A4 266/4885TSHR 2491/4885 |
| US-20200262798-A1 | NOVEL TRIAZINE DERIVATIVE AND PHOTOSENSITIVE COMPOSITION COMPRISING SAME | TYR, CRY2, CRY1 | SYK 1816/4885CYP3A4 322/4885TSHR 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.